CompletedPhase 3

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

United States658 participantsStarted 2014-05

Plain-language summary

To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or Non pregnant females, 18-65 years of age
✓. Signed informed consent obtained that meets all criteria of current FDA and Health Insurance Portability and Accountability Act regulations
✓. Subject has a diagnosis of uncomplicated acute minor ankle sprain: Grade I and II (as defined by the America Academy of Orthopedic Surgeons AAOS)
✓. Ankle sprain must have occurred \< 48 hours before study entry with baseline pain score of \> 50 mm on a 100 mm Visual Analog Scale (VAS) upon active mobilization
✓. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (on stable treatment for at least 3 months) NuvaRing® (vaginal contraceptive); Implanon™ (contraceptive implant) double barrier methods (e.g. condom and spermicide), intrauterine device, or abstinence with a 2nd acceptable method of birth control, should the patient become sexually active. A sterile sexual partner is NOT considered an adequate form of birth control.
✓. All male subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug. Abstinence is an acceptable method of birth control. Female partners should use an acceptable method of birth control as described in Item Number 5.
✓. Subject is free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
✓. Subject shows willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion criteria

✕. Pregnant or breastfeeding female.
✕. Sprain occurred \> 48 hours prior to study enrollment.
✕. Ankle sprain requires an orthopedic or surgical treatment.
✕. Ankle sprain treated prior to study entry by topical, oral, or parenteral nonsteroidal antiinflammatory drug (NSAID), physiotherapy, ultrasound, physical therapy or acupuncture.
✕. Baseline self-evaluation of pain on active mobilization by the VAS \< 50 mm.
✕. Non-intact or damaged skin within the area to be treated, e.g., eczema, psoriasis, exudative, dermatitis, infected lesion, burn or wound.
✕. Medical history of asthma, urticaria, angioedema, bronchospasm, ulcer disease, gastrointestinal bleeding, hypertension, edema, heart failure or cardiovascular disease.
✕. Medical history of any chronic pain disorder.

What they're measuring

Visual Analogue Scale (VAS) Scores at Baseline and Post Treatment

Timeframe: Baseline, 3 days

Trial details

NCT IDNCT02324270

SponsorActavis Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-12

Results submitted2020-04-20

View on ClinicalTrials.gov More Ankle Sprain trials